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Human immunodeficiency virus type 1
protease (HIV-1 PR) is a 99-amino acid,
virally encoded protein responsible for pro-
teolytic cleavage of viral gag and gag-pol
fusion polyproteins into functional prod-
ucts (1-3). The activity of the protease is
required for viral infectivity in vitro (4).
Consequently, HIV-1 PR is an attractive
therapeutic target for rational drug design
(5,6), and the focus of a tremendous
amount ofresearch.
HIV-1 PRhas been characterized as an
aspartic acid protease based on sequence
homology to related enzymes (7, catalytic
pH studies (8), and inhibition by well-
known aspartyl protease inhibitors (9,10).
The active form ofthe enzyme behaves as a
dimer (11,12). These findings have been
confirmed by the elucidation ofX-ray crys-
tallographic structures of the enzyme both
unbound (13-15) and bound to synthetic
inhibitors (16-20).
One feature that distinguishes the
HIV-1 protease from cellular aspartyl pro-
teases is the pH dependence ofits activity.
The optimum pH range for activity ofthe
HIV-1 protease (4.5-6.0) (8) is consider-
ably higher than for cellular enzymes in
vitro (typically 2.0-4.0) (21). A notable
exception is human renin, which has a pH
optimum in the range of 5.5-7.5 (22).
The pH optima ofthese enzymes presum-
ably reflect the catalytic mechanism gener-
ally accepted for aspartyl proteases which
requires one of the catalytic aspartate
residues to be protonated. Recently,
Zhang et al. (23) reported that zinc ions
are inhibitors ofboth renin and HIV-1 PR
at neutral pH. Although the zinc binding
site(s) that lead to inactivation have not
been determined, evidence suggests that
one site may occur at or near the catalytic
aspartate residues. In this study, molecular
dynamics methodology was used to explore
the possibility ofzinc binding in the active
site ofHIV-1 PR and predict the effects of
this binding on the structure. Our results
are consistent with the requirements of
zinc binding reported by Zhang et al. (23)
and give supporting evidence that this is
the site that leads to inhibition of the
protease.
Methods
We performed molecular mechanics and
dynamics calculations using a modified
version ofAMBER3.0 (Revision A) (24,25).
The all-atom force field (26) was used for
all standard residues, and solvent was treat-
ed explicitly using the TIP3P model (27).
Parameters for chloride ions and zinc ions
were taken from Lybrand et al. (28) and
Bartolotti et al. (29), respectively. Elec-
trostatic and van der Waals interactions
were treated using a "twin range" (9/18 A)
residue-based cutoff, updated every 20
steps. We performed simulations under
constant temperature (300 K) and pressure
(1 bar) conditions using a 1-fsec integra-
tion time step, carried out to 200 psec.
We obtained the starting positions of
the heavy atoms for the unbound and
Zn2-bound dimers from the crystallo-
graphic structure of the synthetic
(Aba6795) HIV-1 protease at pH 7.0 (14).
The net charge ofthe unbound dimer was
assumed to be +4, consistent with the nor-
mal protonation states of the component
amino acids at neutral pH. It is possible
that the active site aspartates share a proton
near neutral pH, as maximum protease
activity occurs in the range 4.5-6.0 (8).
However, inflections in the log V/K versus
pH profile observed at pH 3.1 and 5.2
suggest one ofthe aspartates is protonated
at pH 5.2. Since we were simulating the
protease at neutral pH, we chose to treat
both aspartates as being fully charged in
the simulations. In the case of the zinc-
bound protease, it is reasonable to assume
that Zn2+ ion binding (pKa 9.5) (30)
would involve both aspartates in the
unprotonated form.
There was no particular bias in placing
2+.. a Zn ion in the active site a priori.
Instead, the goal was to find the position
of a Zn + ion resulting in the most favor-
able ion-protein potential energy based on
the crystallographic coordinates for the
protein heavy atoms (with hydrogens ener-
gy minimized by AMBER). Using this
position for initial placement of the Zn2+
ion, molecular dynamics may then be used
to refine the binding interactions and
determine the resulting structural changes
in the protein. Initial placement ofa Zn2+
ion was determined by a grid search proce-
dure, whereby the AMBER nonbond
interaction energy (no cutoff) of the ion
was tested on a 0.5 A grid over a 5.0A box
around the crystallographic structure. We
used the grid points corresponding to the
1000 lowest energies as starting points for....r*~2+.
minimization ofa single Zn ion to a root
mean square gradient tolerance of
0.000001 kcal/mol. The position corre-
sponding to the global potential energy
minimum was chosen for the placement of
the ion. Interestingly, this procedure
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resulted in the placement of the Zn2+ ion
in the active site cleft directly between the
carboxylate side chains of the catalytic
aspartate residues.
The net charge ofthe protease and pro-
tease/ion complexes were neutralized with
negatively charged chloride ions using the
same procedure as for the zinc ion. The
solute was solvated in a 13 A water bath
(8013 water molecules) and equilibrated
using the same procedures as for previous
simulations (31). Unconstrained dynamics
was then performed on each system at con-
stant pressure and temperature to 200
psec.
Results
Figure 1 shows the time evolution of the
root mean square deviation of a carbon
atoms with respect to the crystallographic
structure for the molecular dynamics struc-
tures of the unbound and Zn2+-bound
protease. Both systems are well equilibrat-
ed after 150 psec. The unbound protease
equilibrates with a carbon root mean
square deviation of about 1.5 A, whereas
the Zn2-bound structure equilibrates at a
lower value of approximately 1.2 A. Sec-
ondary structural analysis of the crystallo-
graphic structure and the simulation
(150-200 psec) average structures was per-
formed using the Kabsch and Sander pro-
gram DSSP (32). Of the 63 secondary
structural assignments made for the crystal-
lographic monomer, 46 (73%) were con-
served in each monomer of the unbound
structure, and 54 (86%) were conserved in
each monomer of the Zn2+-bound
structure.
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Table 1. Hydrogen bonding atthe dimer interface
X-ray Zn2+bound Unbound
Contact Distance Distance % Time Distance % Time
atom 1-atom 2 (A) (A) bonded (A) bonded
Pro-1 HN+-Phe-99 0 1.71 1.79 100 1.73 100
1.76 100 2.85 46
Pro-1 0-Phe-99 HN 2.16 2.13 86 2.07 93
lle-3 HN-Leu-97 0 1.68 2.12 88 2.09 88
2.12 88 2.03 93
lle-3 O-Leu-97 HN 1.78 1.97 97 1.97 99
1.96 100 1.97 99
Leu-5 O-Arg-87 HN21 2.16 1.97 96 2.03 87
1.91 98 3.39 28
Trp-6 O-Arg-87 HN22 2.23 66 2.60 16
2.09 88 3.81 13
Leu-24 0-Thr-26 HOG 2.55 1.90 99 2.05 93
1.88 100 1.91 100
Thr-26 HN-Thr-26 OG1 2.22 2.02 98 2.29 65
2.05 98 2.03 93
Gly-49 HN-Gly-51 0 2.06 94
Gly-51 HN-Gly-51 0 2.42 1.99 100
His-69 HNE-Phe-99 OXT 2.49
1.99 89
Thr-96 HN-Asn-98 0 2.41 2.03 93 2.00 98
2.03 95 2.01 99
Thr-96 O-Asn-98 HN 2.02 2.00 98 1.94 99
2.03 93 1.96 99
Hydrogen bonds at the dimer interface in the HIV-1 PR crystallographic structure and in the simulations.
Hydrogens were added to the crystallographic structure (X-ray) using AMBER and energy minimized
keeping the nonhydrogen positions fixed. In the unbound and Zn2+-bound simulations, the average H-
bond distances and percenttime the H bond was maintained [definition of an H bond as in York et al. (31)]
are listed for each monomer (monomer 1 is listed on the same line as the H-bond atoms, monomer 2 is
listed immediately below).
Hydrogen Bonding at the Dimer
Interface
An analysis of H-bond contacts at the
dimer interface over the last 50 psec ofthe
simulations has been performed (Table 1).
The primary hydrogen bond interactions
at the dimer interface (33) present in the
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Figure 1. Time evolution of the a carbon root mean square deviation from the crystallographic structure
ofWlodawer et al. (14) forthe unbound protease simulation (thick line) and the Zn2+-bound protease sim-
ulation (thin line).
crystallographic structure are maintained
in solution both in the unbound and Zn2-
bound simulations. These include interac-
tions at the amino- and carboxy-terminal g
strands (residues 1-A, 95-99), which form
a four-stranded antiparallel B sheet, and in
the region ofthe active site triads (residues
25-27), which interlock in the "fireman's
grip" characteristic of aspartyl proteases
(33). In particular, inter-subunit hydrogen
bonds involving residues at or near the
active site (Leu-24, Thr-26, and Arg-87)
were all maintained in the presence of
bound zinc.
Zinc-Protein Interaction
Figure 2 shows the pair distribution func-
tion (34), gab(r), for the carboxylate oxy-
gens ofthe catalytic aspartate residues (Fig.
2a) and water oxygens (Fig. 2b) around the
Zn2+ ion and the corresponding running
integration numbers, which indicate the
average number ofoxygens ofeach type in
a sphere of radius r around the ion. The
pair distribution function for the carboxy-
late oxygens shows a single, sharp peak
centered at 2.13 A, and the corresponding
coordination number, indicated by the
running integration number, is 4. The
pair distribution function for water oxy-
gens shows there are three water molecules
associated with the zinc ion in its first sol-
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Figure 2 Pair distribution function (34), gab(r), of oxygens around the zinc ion during the final 50 psec of
the Zn2-bound simulation (thick lines) for (a) carboxylate oxygens of the catalytic aspartates and (b)
water oxygens. The corresponding running integration numbers are also shown (thin lines).
vation sphere at a distance ofaround 2.25
A. No exchange of oxygens in the first
coordination sphere of zinc was observed
during the last 50 psec of the simulation.
Zinc has been observed to be coordinated
to multiple carboxylate ligands in other
enzymes such as DNA polymerase I from
Escherichia coli(35).
Figure 3 is a stereo picture of the
active-site triads at the dimer interface with
the Zn ion bound to the catalytic aspar-
tates. The crystallographic structure of
Wlodawer et al. (14) is also shown super-
imposed. Inter-subunit H bonds between
Thr-26-*Leu-24' and between Thr-26
<-Thr-26' (primes indicate residues ofthe
symmetry-related monomer), termed the
"fireman's grip," are clearly maintained.
Additionally, the ODI atoms ofthe aspar-
tate side chains maintain H-bond contact
with the backbone amino group ofGly-27
on the same strand. These H bonds are
also pronounced in the crystallographic
structure.
The flap regions of the protease (res-
idues 42-58), which are observed in crys-
tallographic structures to significantly
rearrange upon inhibitor binding (16-20),
were not observed to interact with the zinc
ion in the simulation. Examination ofthe
Gly27'
Figure 3. Stereo picture of the active site triads (residues 25-27 and the corresponding symmetry related residues) for the 150-200 psec Zn2+-bound average
structure showing zinc ion binding tothe active site aspartates. The carbox,ylate oxygens ofthe catalytic aspartates are labeled "0," and inter-subunit hydrogen
bonds are indicated bydotted lines[rz,2+0= 2.13, 2.14A(Asp-25); 2.10, 2.14A(Asp-25')].
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average structure of the zinc-bound pro-
tease indicates the nearest backbone atoms
of the flaps reside more than 9 A away
from the zinc ion.
Discussion
Kinetic studies have shown that zinc is an
effective inhibitor of renin and HIV-1 PR
at pH 7, two aspartyl proteases with pH
optima near neutrality (23). Other studies
of metal ion inhibition of HIV-1 PR per-
formed at pH 5 did not reveal significant
inhibition of the enzyme by Zn2+ ions
(36). Ifinhibition ofHIV-1 PR is a result
ofZn2+ binding at the active-site aspartate
residues, it is reasonable to expect that con-
ditions that favor both aspartates in the
unprotonated form would enhance Zn2+
binding, and hence inhibition. Because
both catalytic aspartates presumably are
unprotonated around neutrality, the ob-
served pH dependence of Zn+2 inhibition
is consistent with binding at or near the
catalytic aspartates. Although the bacteri-
ally expressed HIV-1 PR has three residues
that commonly bind zinc (Cys-67, His-69,
and Cys-95), Zn2+ also inhibits the related
HIV-2 protease, which does not contain
cysteines or histidines [for a discussion of
HIV-2 protease, see Gustchina and Weber
(37) and Tomasselli et al. (38)], in an iden-
tical manner as the HIV-1 protease (23).
This suggests that these residues are not
required binding sites for inactivation by
zinc. Considered with the fact that inhibi-
tion was observed to be first order (23) in
Zn2+, we may infer that there is a single
important binding site that causes inactiva-
tion. Furthermore, inactivation ofthe pro-
tease by zinc was observed to be reversible,
as protease activity could be restored upon
addition ofEDTA(23), which has a higher
affinity than carboxylate moieties for Zn2+
ions. These data are, therefore, consistent
with the requirement ofnoncovalent bind-
ingofZn2 in the active site.
The present study of Zn2+ binding at
the catalytic aspartate residues provides evi-
dence that this is the site responsible for
inactivation of the protease. Evaluation of
the potential energy of a Zn2+ ion in the
field of the crystallographic structure sug-
gests a probable binding site for zinc
occurs in the active site at the catalytic
aspartates (see Methods). Subsequent mol-
ecular dynamics simulations predict that
the zinc ion remains stably bound in this
region; i.e., no exchange of carboxylate
oxygens was observed in the first coordina-
tion sphere of the zinc ion after initial
equilibration. Because the hydrolysis
mechanism mediated by HIV-1 PR re-
quires one ofthe aspartates to be protonat-
ed, forming a hydrogen bond with the car-
bonyl oxygen of the scissile bond and the
other in the unprotonated form to activate
a water molecule for hydrolysis (6), the
coordination ofboth ofthese residues by a
zinc ion would conceivably inactivate the
enzyme. Gel filtration and equilibrium
sedimentation analyses suggest that zinc
binding does not involve disruption ofthe
dimeric structure ofthe protease (23). Our
simulation with bound Zn2+ shows no
weakening ofthe dimer. The overall simu-
lation results indicate that Zn2+ can bind
stably with the catalytic aspartate residues
ofthe HIV-1 protease without significant-
ly disrupting the overall structure. These
results are consistent with experimental
studies and taken together suggest that the
site of Zn + binding that leads to catalytic
inhibition is the active site.
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